Alain Baron (L), Escient CEO and Marcus Boehm, Escient CSO

Thanks to a $77.5M Se­ries B, Escient moves in­to the clin­ic with the first of its sen­so­ry re­cep­tor can­di­dates

A lit­tle over two years af­ter emerg­ing from stealth, Escient Phar­ma­ceu­ti­cals is back Mon­day with a new fundrais­ing round and their first clin­i­cal tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.